Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Impact of genomics on drug discovery and clinical medicine
Autore:
Emilien, G; Ponchon, M; Caldas, C; Isacson, O; Maloteaux, JM;
Indirizzi:
Univ Catholique Louvain, Pharmacol Lab, B-1200 Brussels, Belgium Univ Catholique Louvain Brussels Belgium B-1200 B-1200 Brussels, Belgium Univ Catholique Louvain, Diabet & Nutr Unit, B-1200 Brussels, Belgium UnivCatholique Louvain Brussels Belgium B-1200 B-1200 Brussels, Belgium Univ Catholique Louvain, Dept Neurol, B-1200 Brussels, Belgium Univ Catholique Louvain Brussels Belgium B-1200 B-1200 Brussels, Belgium Univ Cambridge, Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England Univ Cambridge Cambridge England CB2 2QQ col, Cambridge CB2 2QQ, England Harvard Univ, Sch Med, Neuroregenerat Labs, Mclean, VA USA Harvard Univ Mclean VA USA Sch Med, Neuroregenerat Labs, Mclean, VA USA Massachusetts Gen Hosp, Belmont, MA USA Massachusetts Gen Hosp Belmont MAUSA chusetts Gen Hosp, Belmont, MA USA
Titolo Testata:
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
fascicolo: 7, volume: 93, anno: 2000,
pagine: 391 - 423
SICI:
1460-2725(200007)93:7<391:IOGODD>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
LONG-QT SYNDROME; AMYOTROPHIC-LATERAL-SCLEROSIS; DEPENDENT DIABETES-MELLITUS; FAMILIAL ALZHEIMERS-DISEASE; THIOPURINE METHYLTRANSFERASE PHARMACOGENETICS; CARDIOVASCULAR RISK-FACTORS; CILIARY NEUROTROPHIC FACTOR; EPITHELIAL SODIUM-CHANNEL; GROWTH-FACTOR RECEPTOR; VECTOR PRODUCER CELLS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
255
Recensione:
Indirizzi per estratti:
Indirizzo: Emilien, G 127 Rue Henri Prou, F-78340 Les Clayes Bois, France 127 Rue Henri Prou Les Clayes Bois France F-78340 ois, France
Citazione:
G. Emilien et al., "Impact of genomics on drug discovery and clinical medicine", QJM-MON J A, 93(7), 2000, pp. 391-423

Abstract

Genomics, particularly high-throughput sequencing and characterization of expressed human genes, has created new opportunities for drug discovery. Knowledge of all the human genes and their functions may allow effective preventive measures, annd change drug research strategy and drug discovery development processes. Pharmacogenomics is the application of genomic technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. It applies the large-scale systematic approaches of genomics to speed the discovery of drug response markers, whether they act at the level of the drug target, drug metabolism, or disease pathways. The potential implication of genomics and pharmacogenomics in clinical research and clinical medicine is that disease could be treated according to genetic and specific individual markers, selecting medications and dosages that are optimized for individual patients. Thepossibility of defining patient populations genetically may improve outcomes by predicting individual responses to drugs, and could improve safety and efficacy in therapeutic areas such as neuropsychiatry, cardiovascular medicine, endocrinology (diabetes and obesity) and oncology. Ethical questionsneed to be addressed and guidelines established for the use of genomics inclinical research and clinical medicine. Significant achievements are possible with an interdisciplinary approach that includes genetic, technological and therapeutic measures.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 19:00:08